Pegfilgrastim prophylaxis in patients at different levels of risk for chemotherapy-associated febrile neutropenia: an observational study

References

• Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004;100:228-37
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:2258-66
   PubMed Web of Science ®Google Scholar
• Barron R, Michels SL, Reynolds MW, et al. Risk of mortality in patients with cancer experiencing febrile neutropenia [abstract 9561]. J Clin Oncol 2009;27:15s
   Web of Science ®Google Scholar
• Leonard RCF, Miles D, Thomas R, et al. Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients. Br J Cancer 2003;89:2062-8
   PubMed Web of Science ®Google Scholar
• Pettengell R, Schwenkglenks M, Leonard R, et al. Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer 2008;16:1299-309
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995;332:901-6
   PubMed Web of Science ®Google Scholar
• Chirivella I, Bermejo B, Insa A, et al. Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Treat 2009;114:479-84
   PubMed Web of Science ®Google Scholar
• Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011;47:8-32
   PubMed Web of Science ®Google Scholar
• Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205
   PubMed Web of Science ®Google Scholar
• Crawford J, Althaus B, Armitage J, et al. Myeloid growth factors. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2007;5:188-202
   PubMedGoogle Scholar
• Zielinski CC, Awada A, Cameron DA, et al. The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients. Eur J Cancer 2008;44:353-65
   PubMed Web of Science ®Google Scholar
• Neulasta (pegfilgrastim) European prescribing information. Amgen Ltd. Available at: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000420/WC500025945.pdf [Last accessed 21 February 2011]
   Google Scholar
• Schwenkglenks M, Pettengell R, Szucs TD, et al. Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery. J Hematol Oncol 2010;3:27
   PubMed Web of Science ®Google Scholar
• Morrison VA, Wong M, Hershman D, et al. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3–4 week chemotherapy regimens in community oncology practices. J Manag Care Pharm 2007;13:337-48
   PubMed Web of Science ®Google Scholar
• Ozer H, Mirtsching B, Rader M, et al. Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use. Oncologist 2007;12:484-94
   PubMed Web of Science ®Google Scholar
• Lange OF, Stickeler E, Doerfel S, et al. Results of a prospective observational study on the efficacy and safety of pegfilgrastim administered to cancer patients treated with chemotherapy [abstract P663]. Onkologie 2008;31(Suppl 4):195-228
   Google Scholar
• von Minckwitz G, Kümmel S, du Bois A, et al. Pegfilgrastim +/− ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol 2008;19:292-8
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Schwenkglenks M, Skacel T, et al. Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis. Eur J Cancer 2009;45:608-17
   PubMed Web of Science ®Google Scholar
• Holmes FA, O’Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002;20:727-31
   PubMed Web of Science ®Google Scholar
• Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29-35
   PubMed Web of Science ®Google Scholar
• Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005;23:1178-84
   PubMed Web of Science ®Google Scholar
• Lyman GH, Morrison VA, Dale DC, et al. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin’s lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 2003;44:2069-76
   PubMed Web of Science ®Google Scholar